Skip Navigation


European Heart Journal Advance Access originally published online on May 4, 2005
European Heart Journal 2005 26(15):1544-1550; doi:10.1093/eurheartj/ehi305
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/15/1544    most recent
ehi305v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mellin, V.
Right arrow Articles by Mulder, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mellin, V.
Right arrow Articles by Mulder, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure

Virginie Mellin1, Marc Isabelle1, Alexandra Oudot2, Catherine Vergely-Vandriesse2, Christelle Monteil1, Benoit Di Meglio1, Jean Paul Henry1, Brigitte Dautreaux1, Luc Rochette2, Christian Thuillez1 and Paul Mulder1,*

1INSERM U644 (IFRMP no. 23), Faculté de Médecine et Pharmacie, 22 Boulevard Gambetta, 76183 Rouen Cedex, Rouen, France
2Laboratoire de Physiopathologie et Pharmacologie Cardiovasculaires Expérimentales, Dijon, France

Received 29 July 2004; revised 22 March 2005; accepted 31 March 2005; online publish-ahead-of-print 4 May 2005.

* Corresponding author. Tel: +33 2 3514 8359; fax: +33 2 3514 8365. E-mail address: paul.mulder{at}univ-rouen.fr

See page 1458 for the editorial comment on this article (doi:10.1093/eurheartj/ehi321)

Aims Oxidative stress, i.e. imbalance between reactive oxygen species (ROS) and antioxidant defences, contributes to the progression of chronic heart failure (CHF). Acute inhibition of xanthine oxidase (XO), which produces ROS, improves mechanical efficiency of the failing heart, but whether long-term XO inhibition exerts beneficial effects in CHF is unknown.

Methods and results In rats with established CHF induced by left coronary ligation, we assessed the effects of a 5-day and a 10-week treatment with the XO inhibitor allopurinol (50 mg kg–1 day–1) on haemodynamics and left ventricular (LV) function and structure. Both acute and chronic allopurinol treatment increase cardiac output without modification of arterial pressure, but only chronic allopurinol treatment reduces LV end-diastolic pressure and LV relaxation constant. Chronic allopurinol treatment decreases both LV systolic and diastolic diameters, but acute allopurinol treatment only decreases LV systolic diameter. Moreover, chronic allopurinol decreases LV weight and collagen density. Despite XO inhibition after acute and chronic allopurinol treatment, as both treatments reduce uric acid plasma levels, only acute allopurinol treatment reduces LV ROS determined using electron spin resonance spectroscopy. However, the CHF-enhanced myocardial thiobarbituric acid reactive substances levels were never modified.

Conclusion In experimental CHF, long-term allopurinol treatment, initiated in a pathological state of overt CHF, improves LV haemodynamics and function and prevents LV remodelling. These long-term effects are, at least partially, caused by a transient reduction of myocardial ROS shortly after initiation of allopurinol treatment, but whether other mechanism(s), independent of myocardial redox ‘status’, such as reduced inflammation, are implicated remains to be confirmed.

Key Words: Heart failure • Allopurinol • Reactive oxygen species


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Xanthine oxidase inhibitors: an emerging class of drugs for heart failure
Michelle M. Kittleson and Joshua M. Hare
EHJ 2005 26: 1458-1460. [Extract] [Full Text]  



This article has been cited by other articles:


Home page
 Eur Heart JHome page
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al.
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
Eur. Heart J., June 27, 2008; (2008) ehn277v1.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. M. Hare, B. Mangal, J. Brown, C. Fisher Jr, R. Freudenberger, W. S. Colucci, D. L. Mann, P. Liu, M. M. Givertz, R. P. Schwarz, et al.
Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2301 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. Ramasubbu, J. Estep, D. L. White, A. Deswal, and D. L. Mann
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
J. Am. Coll. Cardiol., January 29, 2008; 51(4): 415 - 426.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. George, E. Carr, J. Davies, J.J.F. Belch, and A. Struthers
High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid
Circulation, December 5, 2006; 114(23): 2508 - 2516.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. M. Zimmet and J. M. Hare
Nitroso-Redox Interactions in the Cardiovascular System
Circulation, October 3, 2006; 114(14): 1531 - 1544.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
R. J. Hajjar and J. A. Leopold
Xanthine Oxidase Inhibition and Heart Failure: Novel Therapeutic Strategy for Ventricular Dysfunction?
Circ. Res., February 3, 2006; 98(2): 169 - 171.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
K. M. Minhas, R. M. Saraiva, K. H. Schuleri, S. Lehrke, M. Zheng, A. P. Saliaris, C. E. Berry, K. M. Vandegaer, D. Li, and J. M. Hare
Xanthine Oxidoreductase Inhibition Causes Reverse Remodeling in Rats With Dilated Cardiomyopathy
Circ. Res., February 3, 2006; 98(2): 271 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. M. Kittleson and J. M. Hare
Xanthine oxidase inhibitors: an emerging class of drugs for heart failure
Eur. Heart J., August 1, 2005; 26(15): 1458 - 1460.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.